EUROBIO-SCIENTIFIC (ALERS.PA) Stock Fundamental Analysis
Europe - EPA:ALERS - FR0013240934 - Common Stock
24.4 EUR
+0.25 (+1.04%)
Overall ALERS gets a fundamental rating of 6 out of 10. We evaluated ALERS against 75 industry peers in the Biotechnology industry. ALERS has an excellent financial health rating, but there are some minor concerns on its profitability. ALERS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ALERS had positive earnings in the past year.
ALERS had a positive operating cash flow in the past year.
Each year in the past 5 years ALERS has been profitable.
ALERS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ALERS's Return On Assets of 0.91% is fine compared to the rest of the industry. ALERS outperforms 74.67% of its industry peers.
ALERS's Return On Equity of 1.30% is fine compared to the rest of the industry. ALERS outperforms 78.67% of its industry peers.
The Return On Invested Capital of ALERS (4.00%) is better than 77.33% of its industry peers.
ALERS had an Average Return On Invested Capital over the past 3 years of 5.13%. This is significantly below the industry average of 12.96%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.91% | ||
| ROE | 1.3% | ||
| ROIC | 4% |
ROA(3y)3.54%
ROA(5y)16.42%
ROE(3y)6.48%
ROE(5y)25.15%
ROIC(3y)5.13%
ROIC(5y)17.09%
1.3 Margins
With a decent Profit Margin value of 1.46%, ALERS is doing good in the industry, outperforming 76.00% of the companies in the same industry.
ALERS's Profit Margin has declined in the last couple of years.
The Operating Margin of ALERS (7.62%) is better than 77.33% of its industry peers.
In the last couple of years the Operating Margin of ALERS has grown nicely.
ALERS has a Gross Margin of 46.95%. This is comparable to the rest of the industry: ALERS outperforms 48.00% of its industry peers.
In the last couple of years the Gross Margin of ALERS has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.62% | ||
| PM (TTM) | 1.46% | ||
| GM | 46.95% |
OM growth 3Y-38.55%
OM growth 5Y55.68%
PM growth 3Y-57.11%
PM growth 5Y-13.49%
GM growth 3Y-5.65%
GM growth 5Y7%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALERS is destroying value.
The number of shares outstanding for ALERS remains at a similar level compared to 1 year ago.
The number of shares outstanding for ALERS has been reduced compared to 5 years ago.
ALERS has a better debt/assets ratio than last year.
2.2 Solvency
ALERS has an Altman-Z score of 3.74. This indicates that ALERS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 3.74, ALERS belongs to the best of the industry, outperforming 81.33% of the companies in the same industry.
The Debt to FCF ratio of ALERS is 1.48, which is an excellent value as it means it would take ALERS, only 1.48 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.48, ALERS belongs to the top of the industry, outperforming 86.67% of the companies in the same industry.
ALERS has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.07, ALERS is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 1.48 | ||
| Altman-Z | 3.74 |
ROIC/WACC0.56
WACC7.12%
2.3 Liquidity
A Current Ratio of 1.79 indicates that ALERS should not have too much problems paying its short term obligations.
ALERS has a Current ratio (1.79) which is comparable to the rest of the industry.
ALERS has a Quick Ratio of 1.25. This is a normal value and indicates that ALERS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.25, ALERS is doing worse than 62.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.25 |
3. Growth
3.1 Past
The earnings per share for ALERS have decreased strongly by -63.15% in the last year.
Measured over the past 5 years, ALERS shows a small growth in Earnings Per Share. The EPS has been growing by 6.82% on average per year.
ALERS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.47%.
The Revenue has been growing by 21.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-63.15%
EPS 3Y-58.79%
EPS 5Y6.82%
EPS Q2Q%-41.15%
Revenue 1Y (TTM)12.47%
Revenue growth 3Y-5.77%
Revenue growth 5Y21.21%
Sales Q2Q%10.27%
3.2 Future
Based on estimates for the next years, ALERS will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.32% on average per year.
Based on estimates for the next years, ALERS will show a quite strong growth in Revenue. The Revenue will grow by 12.90% on average per year.
EPS Next Y-11.36%
EPS Next 2Y13.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.03%
Revenue Next 2Y12.9%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ALERS is valuated quite expensively with a Price/Earnings ratio of 106.09.
Based on the Price/Earnings ratio, ALERS is valued a bit cheaper than 73.33% of the companies in the same industry.
ALERS is valuated expensively when we compare the Price/Earnings ratio to 25.47, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 20.96, ALERS is valued on the expensive side.
85.33% of the companies in the same industry are more expensive than ALERS, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.42, ALERS is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 106.09 | ||
| Fwd PE | 20.96 |
4.2 Price Multiples
ALERS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALERS is cheaper than 88.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALERS indicates a rather cheap valuation: ALERS is cheaper than 82.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.1 | ||
| EV/EBITDA | 7.81 |
4.3 Compensation for Growth
ALERS has a very decent profitability rating, which may justify a higher PE ratio.
ALERS's earnings are expected to grow with 13.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)15.56
EPS Next 2Y13.32%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ALERS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALERS (11/19/2025, 7:00:00 PM)
24.4
+0.25 (+1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.86%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap250.10M
Revenue(TTM)162.09M
Net Income(TTM)2.36M
Analysts84.44
Price Target30.6 (25.41%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-32.76%
EPS NY rev (3m)-32.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)11.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 106.09 | ||
| Fwd PE | 20.96 | ||
| P/S | 1.54 | ||
| P/FCF | 22.1 | ||
| P/OCF | 17.43 | ||
| P/B | 1.38 | ||
| P/tB | 7.72 | ||
| EV/EBITDA | 7.81 |
EPS(TTM)0.23
EY0.94%
EPS(NY)1.16
Fwd EY4.77%
FCF(TTM)1.1
FCFY4.53%
OCF(TTM)1.4
OCFY5.74%
SpS15.81
BVpS17.71
TBVpS3.16
PEG (NY)N/A
PEG (5Y)15.56
Graham Number9.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.91% | ||
| ROE | 1.3% | ||
| ROCE | 6.02% | ||
| ROIC | 4% | ||
| ROICexc | 4.6% | ||
| ROICexgc | 27.98% | ||
| OM | 7.62% | ||
| PM (TTM) | 1.46% | ||
| GM | 46.95% | ||
| FCFM | 6.98% |
ROA(3y)3.54%
ROA(5y)16.42%
ROE(3y)6.48%
ROE(5y)25.15%
ROIC(3y)5.13%
ROIC(5y)17.09%
ROICexc(3y)7.07%
ROICexc(5y)35.47%
ROICexgc(3y)44.03%
ROICexgc(5y)78.19%
ROCE(3y)7.73%
ROCE(5y)25.78%
ROICexgc growth 3Y-35.35%
ROICexgc growth 5Y49.79%
ROICexc growth 3Y-58%
ROICexc growth 5Y39.27%
OM growth 3Y-38.55%
OM growth 5Y55.68%
PM growth 3Y-57.11%
PM growth 5Y-13.49%
GM growth 3Y-5.65%
GM growth 5Y7%
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 1.48 | ||
| Debt/EBITDA | 0.41 | ||
| Cap/Depr | 16.48% | ||
| Cap/Sales | 1.87% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 46.68% | ||
| Profit Quality | 479.21% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.25 | ||
| Altman-Z | 3.74 |
F-Score6
WACC7.12%
ROIC/WACC0.56
Cap/Depr(3y)26.09%
Cap/Depr(5y)27.29%
Cap/Sales(3y)2.36%
Cap/Sales(5y)1.86%
Profit Quality(3y)322.49%
Profit Quality(5y)228.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-63.15%
EPS 3Y-58.79%
EPS 5Y6.82%
EPS Q2Q%-41.15%
EPS Next Y-11.36%
EPS Next 2Y13.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.47%
Revenue growth 3Y-5.77%
Revenue growth 5Y21.21%
Sales Q2Q%10.27%
Revenue Next Year22.03%
Revenue Next 2Y12.9%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.09%
EBIT growth 3Y-42.09%
EBIT growth 5Y88.7%
EBIT Next Year35.62%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.22%
FCF growth 3Y-40.57%
FCF growth 5Y31.67%
OCF growth 1Y-50.55%
OCF growth 3Y-36.72%
OCF growth 5Y27.33%
EUROBIO-SCIENTIFIC / ALERS.PA FAQ
What is the ChartMill fundamental rating of EUROBIO-SCIENTIFIC (ALERS.PA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to ALERS.PA.
Can you provide the valuation status for EUROBIO-SCIENTIFIC?
ChartMill assigns a valuation rating of 5 / 10 to EUROBIO-SCIENTIFIC (ALERS.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for EUROBIO-SCIENTIFIC?
EUROBIO-SCIENTIFIC (ALERS.PA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of EUROBIO-SCIENTIFIC (ALERS.PA) stock?
The Price/Earnings (PE) ratio for EUROBIO-SCIENTIFIC (ALERS.PA) is 106.09 and the Price/Book (PB) ratio is 1.38.